ABSI Absci Corporation - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ABSI Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$2.55
Analyst Target
$8.05
+215.5%
Upside
52W High
$6.33
52W Low
$2.01
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$383.45M
P/E
N/A
ROE
-55.7%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
87%
Analysis Accuracy
ABSI's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises red flags for potential bankruptcy risk. The company exhibits catastrophic profitability metrics, including a -7,977.25% operating margin and negative ROE/ROA, alongside a 77.8% year-over-year revenue decline. Despite a modest insider sentiment score of 60/100, recent insider selling activity and a bearish technical trend further undermine confidence. The stock trades at a premium valuation (Price/Sales of 136.22) with no earnings or cash flow support, and analyst targets remain unconvincing without consensus. Overall, the fundamentals are deeply compromised.
Key Strengths
Insider sentiment remains moderately positive at 60/100, suggesting some internal confidence
Strong current and quick ratios (5.89 and 5.17) indicate robust short-term liquidity
Low debt-to-equity ratio (0.03) implies minimal leverage risk
Recent quarter showed a positive Q/Q EPS growth of +16.7%, signaling potential improvement in losses
Peer comparison shows some biotech peers with similar or worse metrics but higher returns, suggesting potential for recovery
Key Risks
Piotroski F-Score of 1/9 is critically low, indicating severe financial deterioration and operational failure
Operating margin of -7,977.25% and negative ROE/ROA reflect deep unprofitability and capital inefficiency
77.8% YoY revenue decline signals a failing business model or market rejection
No meaningful cash flow or free cash flow data, raising concerns about sustainability
Insider selling of $0.13M in the last 6 months, with two high-level executives exiting, signals potential internal concerns
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
14
Weak
15
25
18
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative profitability and revenue contraction, Lack of cash flow and earnings, Insider selling, Premium valuation without earnings support
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Low debt-to-equity ratio (0.03) suggests financial prudence
Watchpoints
- Price/Sales of 136.22 is extremely high for a company with negative earnings and shrinking revenue
- No Graham Number or intrinsic value available, indicating no defensive valuation floor
- Forward P/E of -3.62 confirms ongoing losses and no earnings recovery in sight
Future
25/100
Ref Growth rates
Positives
- Q/Q EPS growth of +16.7% suggests potential improvement in loss rate
- Analyst target price of $8.05 implies upside potential if turnaround occurs
Watchpoints
- 77.8% YoY revenue decline indicates ongoing business deterioration
- No forward earnings guidance or positive growth trajectory
- No free cash flow or operating cash flow data to support future viability
Past
18/100
Ref Historical trends
Positives
- Some quarters beat estimates (e.g., +15.3% surprise in 2023-03-30)
- Historical earnings surprise average of -2.19% over last 4 quarters shows mixed performance
Watchpoints
- Consistent negative earnings surprises over multiple quarters
- 2021-09-07 earnings beat was an outlier (+13.7%) amid extreme losses
- Long-term price decline: -88.2% over 5 years
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High current and quick ratios (5.89 and 5.17) indicate strong liquidity
- Low debt-to-equity (0.03) suggests minimal financial risk
Watchpoints
- Piotroski F-Score of 1/9 is among the weakest possible, signaling systemic failure
- No Altman Z-Score available, but the financial metrics suggest distress risk
- Negative ROE (-55.68%) and ROA (-30.62%) indicate capital destruction
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield, rate, or payout ratio
- Dividend strength is 0/100, indicating no dividend policy
- Company is not generating profits, making dividends impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.55
Analyst Target
$8.05
Upside/Downside
+215.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABSI and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABSI
Absci Corporation
Primary
|
-88.2% | -5.2% | -49.0% | -13.0% | -23.9% | -5.4% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-42.6% | +262.8% | +3.5% | -21.9% | -45.7% | -2.1% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-63.3% | +88.4% | -43.1% | -61.8% | -20.0% | 0.0% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.62
PEG Ratio
N/A
P/B Ratio
1.81
P/S Ratio
136.22
EV/Revenue
84.26
EV/EBITDA
-2.25
Market Cap
$383.45M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-7977.25%
Gross Margin
N/A
ROE
-55.68%
ROA
-30.62%
Growth
Revenue and earnings growth rates
Revenue Growth
-77.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
5.89
Strong
Quick Ratio
5.17
Excellent
Cash/Share
$1.01
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-17
$N/A
2025-11-12
$-0.2
+2.5% surprise
2025-08-12
$-0.24
-15.1% surprise
2025-05-13
$-0.21
+6.0% surprise
Healthcare Sector Comparison
Comparing ABSI against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-55.68%
This Stock
vs
-56.84%
Sector Avg
-2.1%
(Below Avg)
Debt to Equity
0.03
This Stock
vs
2.68
Sector Avg
-98.9%
(Less Debt)
Revenue Growth
-77.8%
This Stock
vs
61.93%
Sector Avg
-225.6%
(Slower)
Current Ratio
5.89
This Stock
vs
3.47
Sector Avg
+69.9%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABSI
Absci Corporation
|
BEARISH | $383.45M | - | -55.7% | -% | $2.55 | |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $395.29M | - | -% | -158.9% | $3.24 | |
|
AKBA
Akebia Therapeutics, Inc.
|
NEUTRAL | $360.9M | - | -% | -7.1% | $1.36 | |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-02 | MCCLAIN SEAN | Chief Executive Officer | Sale | 26,761 | $80,015 |
| 2026-02-02 | JONASSON ZACHARIAH | Chairman of the Board | Sale | 17,496 | $52,313 |
| 2026-01-28 | BEDRICK TODD | Officer | Stock Award | 15,000 | - |
| 2025-12-05 | VAN HOUTEN FRANS | Director | Purchase | 40,000 | $148,800 |
| 2025-09-22 | BEDRICK TODD | Officer | Purchase | 10,000 | $27,000 |
| 2025-09-22 | PANGALOS MENELAS N | Director | Purchase | 95,785 | $254,788 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
HC Wainwright & Co.
2025-12-18
Buy
Buy
Needham
2025-12-12
Buy
Buy
Needham
2025-11-13
Buy
Buy
JP Morgan
2025-10-02
Overweight
Morgan Stanley
2025-08-18
Overweight
Overweight
Past News Coverage
Recent headlines mentioning ABSI from our newsroom.
Newest → oldest
No matching news yet.